<s id="wsj_1246.1"> 22
2 	 0 	 N/N 	 1 	 scientists Two
2 	 1 	 N/N 	 1 	 scientists Japanese
2 	 3 	 (S[dcl]\NP)/S[dcl] 	 1 	 scientists said
4 	 5 	 (S[dcl]\NP)/NP 	 1 	 they discovered
5 	 3 	 (S[dcl]\NP)/S[dcl] 	 2 	 discovered said
7 	 5 	 (S[dcl]\NP)/NP 	 2 	 antibody discovered
7 	 6 	 NP[nb]/N 	 1 	 antibody an
7 	 8 	 (NP\NP)/(S[dcl]\NP) 	 1 	 antibody that
7 	 15 	 (S[dcl]\NP)/NP 	 1 	 antibody kills <XB>
7 	 19 	 (S[ng]\NP)/NP 	 1 	 antibody preserving <XB>
13 	 10 	 ((S\NP)/(S\NP))/NP 	 3 	 experiments in
13 	 11 	 N/N 	 1 	 experiments laboratory
13 	 12 	 N/N 	 1 	 experiments test-tube
15 	 8 	 (NP\NP)/(S[dcl]\NP) 	 2 	 kills that
15 	 10 	 ((S\NP)/(S\NP))/NP 	 2 	 kills in
15 	 18 	 ((S\NP)\(S\NP))/(S[ng]\NP) 	 2 	 kills while
17 	 15 	 (S[dcl]\NP)/NP 	 2 	 cells kills
17 	 16 	 N/N 	 1 	 cells AIDS-infected
19 	 18 	 ((S\NP)\(S\NP))/(S[ng]\NP) 	 3 	 preserving while
21 	 19 	 (S[ng]\NP)/NP 	 2 	 cells preserving
21 	 20 	 N/N 	 1 	 cells healthy
<\s>
<s id="wsj_1246.2"> 20
2 	 1 	 N/N 	 1 	 experiments further
2 	 3 	 (S[dcl]\NP)/(S[adj]\NP) 	 1 	 experiments are
2 	 4 	 S[adj]\NP 	 1 	 experiments successful <XB>
3 	 0 	 (S/S)/S[dcl] 	 2 	 are If
4 	 3 	 (S[dcl]\NP)/(S[adj]\NP) 	 2 	 successful are
7 	 6 	 NP[nb]/N 	 1 	 work the
7 	 8 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 work would
7 	 9 	 (S[b]\NP)/NP 	 1 	 work represent <XB>
8 	 0 	 (S/S)/S[dcl] 	 1 	 would If
9 	 8 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 represent would
12 	 9 	 (S[b]\NP)/NP 	 2 	 advance represent
12 	 10 	 NP[nb]/N 	 1 	 advance a
12 	 11 	 N/N 	 1 	 advance major
12 	 13 	 (NP\NP)/NP 	 1 	 advance in
14 	 13 	 (NP\NP)/NP 	 2 	 research in
14 	 15 	 (NP\NP)/NP 	 1 	 research on
19 	 15 	 (NP\NP)/NP 	 2 	 syndrome on
19 	 16 	 N/N 	 1 	 syndrome acquired
19 	 17 	 N/N 	 1 	 syndrome immune
19 	 18 	 N/N 	 1 	 syndrome deficiency
<\s>
<s id="wsj_1246.3"> 26
2 	 0 	 NP[nb]/N 	 1 	 AZT The
2 	 1 	 N/N 	 1 	 AZT drug
2 	 12 	 (S[dcl]\NP)/(S[to]\NP) 	 1 	 AZT claims
2 	 15 	 (S[b]\NP)/(S[b]\NP) 	 1 	 AZT help <XB>
2 	 16 	 (S[b]\NP)/NP 	 1 	 AZT stop <XB>
2 	 24 	 (S[b]\NP)/NP 	 1 	 AZT cure <XU>
6 	 4 	 NP[nb]/N 	 1 	 treatment the
6 	 5 	 N/N 	 1 	 treatment only
6 	 8 	 (NP\NP)/NP 	 1 	 treatment on
6 	 12 	 (S[dcl]\NP)/(S[to]\NP) 	 1 	 treatment claims
6 	 15 	 (S[b]\NP)/(S[b]\NP) 	 1 	 treatment help <XB>
6 	 16 	 (S[b]\NP)/NP 	 1 	 treatment stop <XB>
6 	 24 	 (S[b]\NP)/NP 	 1 	 treatment cure <XU>
8 	 7 	 (NP\NP)/(NP\NP) 	 2 	 on currently
10 	 8 	 (NP\NP)/NP 	 2 	 market on
10 	 9 	 NP[nb]/N 	 1 	 market the
14 	 12 	 (S[dcl]\NP)/(S[to]\NP) 	 2 	 to claims
14 	 13 	 (S\NP)/(S\NP) 	 2 	 to only
15 	 14 	 (S[to]\NP)/(S[b]\NP) 	 2 	 help to
16 	 15 	 (S[b]\NP)/(S[b]\NP) 	 2 	 stop help
18 	 16 	 (S[b]\NP)/NP 	 2 	 spread stop
18 	 17 	 NP[nb]/N 	 1 	 spread the
18 	 19 	 (NP\NP)/NP 	 1 	 spread of
20 	 19 	 (NP\NP)/NP 	 2 	 AIDS of
23 	 12 	 (S[dcl]\NP)/(S[to]\NP) 	 2 	 to claims
23 	 22 	 (S\NP)/(S\NP) 	 2 	 to not
24 	 23 	 (S[to]\NP)/(S[b]\NP) 	 2 	 cure to
25 	 24 	 (S[b]\NP)/NP 	 2 	 it cure
<\s>
<s id="wsj_1246.4"> 29
2 	 1 	 N/N 	 1 	 analysts several
2 	 6 	 S[adj]\NP 	 1 	 analysts familiar <XB>
2 	 21 	 ((S[dcl]\NP)/PP)/NP 	 1 	 analysts expressed
5 	 4 	 N/N 	 1 	 scientists Japanese
5 	 6 	 S[adj]\NP 	 1 	 scientists familiar <XB>
5 	 21 	 ((S[dcl]\NP)/PP)/NP 	 1 	 scientists expressed
6 	 7 	 ((S[adj]\NP)\(S[adj]\NP))/NP 	 2 	 familiar with
9 	 7 	 ((S[adj]\NP)\(S[adj]\NP))/NP 	 3 	 study with
9 	 8 	 NP[nb]/N 	 1 	 study the
9 	 11 	 (NP\NP)/(S[dcl]\NP) 	 1 	 study which
9 	 12 	 (S[dcl]\NP)/(S[pss]\NP) 	 1 	 study was <XB>
9 	 13 	 S[pss]\NP 	 1 	 study announced <XB>
12 	 11 	 (NP\NP)/(S[dcl]\NP) 	 2 	 was which
13 	 12 	 (S[dcl]\NP)/(S[pss]\NP) 	 2 	 announced was
13 	 14 	 ((S\NP)\(S\NP))/NP 	 2 	 announced at
13 	 19 	 (S\NP)\(S\NP) 	 2 	 announced yesterday
16 	 14 	 ((S\NP)\(S\NP))/NP 	 3 	 conference at
16 	 15 	 NP[nb]/N 	 1 	 conference a
16 	 17 	 (NP\NP)/NP 	 1 	 conference in
18 	 17 	 (NP\NP)/NP 	 2 	 Nagoya in
21 	 0 	 S/S 	 1 	 expressed But
22 	 21 	 ((S[dcl]\NP)/PP)/NP 	 3 	 skepticism expressed
23 	 21 	 ((S[dcl]\NP)/PP)/NP 	 2 	 over expressed
25 	 23 	 PP/NP 	 1 	 significance over
25 	 24 	 NP[nb]/N 	 1 	 significance the
25 	 26 	 (NP\NP)/NP 	 1 	 significance of
28 	 26 	 (NP\NP)/NP 	 2 	 results of
28 	 27 	 NP[nb]/N 	 1 	 results the
<\s>
<s id="wsj_1246.5"> 23
2 	 1 	 NP[nb]/N 	 1 	 researchers the
2 	 3 	 NP\NP 	 1 	 researchers themselves
2 	 4 	 (S[dcl]\NP)/S[dcl] 	 1 	 researchers acknowledged
4 	 0 	 S/S 	 1 	 acknowledged And
5 	 7 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 they must
5 	 8 	 (S[b]\NP)/NP 	 1 	 they do <XB>
7 	 4 	 (S[dcl]\NP)/S[dcl] 	 2 	 must acknowledged
7 	 6 	 (S\NP)/(S\NP) 	 2 	 must still
8 	 7 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 do must
8 	 12 	 ((S\NP)\(S\NP))/S[dcl] 	 2 	 do before
10 	 9 	 (N/N)/(N/N) 	 2 	 more much
11 	 8 	 (S[b]\NP)/NP 	 2 	 work do
11 	 10 	 N/N 	 1 	 work more
13 	 14 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 they can
13 	 15 	 (S[b]\NP)/S[qem] 	 1 	 they say <XB>
14 	 12 	 ((S\NP)\(S\NP))/S[dcl] 	 3 	 can before
15 	 14 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 say can
16 	 15 	 (S[b]\NP)/S[qem] 	 2 	 whether say
18 	 17 	 NP[nb]/N 	 1 	 treatment the
18 	 19 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 treatment would
18 	 21 	 (S[b]\NP)/NP 	 1 	 treatment cure <XB>
19 	 16 	 S[qem]/S[dcl] 	 1 	 would whether
19 	 20 	 (S\NP)\(S\NP) 	 2 	 would actually
21 	 19 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 cure would
22 	 21 	 (S[b]\NP)/NP 	 2 	 humans cure
<\s>
<s id="wsj_1246.6"> 36
1 	 0 	 N/N 	 1 	 Yonehara Shin
1 	 15 	 (S[dcl]\NP)/S[dcl] 	 1 	 Yonehara said
5 	 3 	 NP[nb]/N 	 1 	 scientist a
5 	 4 	 N/N 	 1 	 scientist research
5 	 6 	 (NP\NP)/NP 	 1 	 scientist at
5 	 15 	 (S[dcl]\NP)/S[dcl] 	 1 	 scientist said
10 	 6 	 (NP\NP)/NP 	 2 	 Institute at
10 	 7 	 NP[nb]/N 	 1 	 Institute the
10 	 8 	 N/N 	 1 	 Institute Tokyo
10 	 9 	 N/N 	 1 	 Institute Metropolitan
10 	 11 	 (NP\NP)/NP 	 1 	 Institute of
13 	 11 	 (NP\NP)/NP 	 2 	 Science of
13 	 12 	 N/N 	 1 	 Science Medical
17 	 16 	 NP[nb]/N 	 1 	 antibody the
17 	 19 	 (S[dcl]\NP)/NP 	 2 	 antibody discovered <XU>
17 	 20 	 S[dcl]\NP 	 1 	 antibody works
17 	 22 	 (S[ng]\NP)/NP 	 1 	 antibody recognizing <XB>
18 	 19 	 (S[dcl]\NP)/NP 	 1 	 he discovered
20 	 15 	 (S[dcl]\NP)/S[dcl] 	 2 	 works said
20 	 21 	 ((S\NP)\(S\NP))/(S[ng]\NP) 	 2 	 works by
22 	 21 	 ((S\NP)\(S\NP))/(S[ng]\NP) 	 3 	 recognizing by
24 	 22 	 (S[ng]\NP)/NP 	 2 	 antigen recognizing
24 	 23 	 NP[nb]/N 	 1 	 antigen an
24 	 25 	 (S[pss]\NP)/NP 	 1 	 antigen called <XB>
24 	 29 	 (NP\NP)/(S[dcl]\NP) 	 1 	 antigen which
24 	 30 	 (S[dcl]\NP)/(S[adj]\NP) 	 1 	 antigen is <XB>
24 	 31 	 (S[adj]\NP)/PP 	 1 	 antigen characteristic <XB>
27 	 25 	 (S[pss]\NP)/NP 	 2 	 Fas-antigen called
27 	 26 	 NP[nb]/N 	 1 	 Fas-antigen a
30 	 29 	 (NP\NP)/(S[dcl]\NP) 	 2 	 is which
31 	 30 	 (S[dcl]\NP)/(S[adj]\NP) 	 2 	 characteristic is
32 	 31 	 (S[adj]\NP)/PP 	 2 	 of characteristic
35 	 32 	 PP/NP 	 1 	 cell of
35 	 33 	 NP[nb]/N 	 1 	 cell an
35 	 34 	 N/N 	 1 	 cell infected
<\s>
<s id="wsj_1246.7"> 6
1 	 0 	 NP[nb]/N 	 1 	 antibody The
1 	 3 	 (S[dcl]\NP)/NP 	 1 	 antibody kills
3 	 2 	 (S\NP)/(S\NP) 	 2 	 kills then
5 	 3 	 (S[dcl]\NP)/NP 	 2 	 cell kills
5 	 4 	 NP[nb]/N 	 1 	 cell the
<\s>
<s id="wsj_1246.8"> 32
1 	 0 	 N/N 	 1 	 Yonehara Dr.
1 	 12 	 (S[dcl]\NP)/S[dcl] 	 1 	 Yonehara said
4 	 3 	 NP[nb]/N 	 1 	 partner his
4 	 12 	 (S[dcl]\NP)/S[dcl] 	 1 	 partner said
7 	 6 	 N/N 	 1 	 Kobayashi Nobuyuki
7 	 8 	 (NP\NP)/NP 	 1 	 Kobayashi of
7 	 12 	 (S[dcl]\NP)/S[dcl] 	 1 	 Kobayashi said
10 	 8 	 (NP\NP)/NP 	 2 	 University of
10 	 9 	 N/N 	 1 	 University Yamaguchi
14 	 13 	 NP[nb]/N 	 1 	 experiments their
14 	 15 	 (S[dcl]\NP)/S[em] 	 1 	 experiments showed
15 	 12 	 (S[dcl]\NP)/S[dcl] 	 2 	 showed said
16 	 15 	 (S[dcl]\NP)/S[em] 	 2 	 that showed
18 	 17 	 NP[nb]/N 	 1 	 antibody the
18 	 19 	 (S[dcl]\NP)/NP 	 1 	 antibody wiped
19 	 16 	 S[em]/S[dcl] 	 1 	 wiped that
19 	 20 	 (S\NP)\(S\NP) 	 2 	 wiped out
19 	 29 	 ((S\NP)\(S\NP))/NP 	 2 	 wiped within
22 	 19 	 (S[dcl]\NP)/NP 	 2 	 average wiped
22 	 21 	 NP[nb]/N 	 1 	 average an
22 	 23 	 (NP\NP)/NP 	 1 	 average of
25 	 23 	 (NP\NP)/NP 	 2 	 % of
25 	 24 	 N/N 	 1 	 % 60
25 	 26 	 (NP\NP)/NP 	 1 	 % of
28 	 26 	 (NP\NP)/NP 	 2 	 cells of
28 	 27 	 N/N 	 1 	 cells AIDS-infected
31 	 29 	 ((S\NP)\(S\NP))/NP 	 3 	 days within
31 	 30 	 N/N 	 1 	 days three
<\s>
<s id="wsj_1246.9"> 17
1 	 0 	 (S/S)/NP 	 2 	 some In
1 	 2 	 (NP\NP)/NP 	 1 	 some of
4 	 2 	 (NP\NP)/NP 	 2 	 experiments of
4 	 3 	 NP[nb]/N 	 1 	 experiments the
6 	 7 	 (S[dcl]\NP)/NP 	 1 	 it killed
7 	 0 	 (S/S)/NP 	 1 	 killed In
7 	 16 	 (S[dcl]\S[dcl])\NP 	 1 	 killed said
9 	 8 	 (NP/NP)/(NP/NP) 	 2 	 all almost
12 	 7 	 (S[dcl]\NP)/NP 	 2 	 cells killed
12 	 9 	 NP/NP 	 1 	 cells all
12 	 10 	 NP[nb]/N 	 1 	 cells the
12 	 11 	 N/N 	 1 	 cells infected
15 	 14 	 NP[nb]/N 	 1 	 researchers the
15 	 16 	 (S[dcl]\S[dcl])\NP 	 2 	 researchers said
<\s>
<s id="wsj_1246.10"> 12
2 	 3 	 ((N/N)/(N/N))\(S[adj]\NP) 	 3 	 fewer than
4 	 3 	 ((N/N)/(N/N))\(S[adj]\NP) 	 2 	 10 than
5 	 4 	 N/N 	 1 	 % 10
5 	 6 	 (NP\NP)/NP 	 1 	 % of
5 	 10 	 (S[dcl]\NP)/(S[pss]\NP) 	 1 	 % were
5 	 11 	 S[pss]\NP 	 1 	 % killed <XB>
9 	 6 	 (NP\NP)/NP 	 2 	 cells of
9 	 7 	 NP[nb]/N 	 1 	 cells the
9 	 8 	 N/N 	 1 	 cells healthy
10 	 0 	 S/S 	 1 	 were Meanwhile
11 	 10 	 (S[dcl]\NP)/(S[pss]\NP) 	 2 	 killed were
<\s>
<s id="wsj_1246.11"> 15
1 	 0 	 NP[nb]/N 	 1 	 two The
1 	 2 	 (S[dcl]\NP)/S[dcl] 	 1 	 two said
3 	 4 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 they must
3 	 6 	 (S[b]\NP)/NP 	 1 	 they do <XB>
3 	 12 	 (S[b]\NP)/PP 	 1 	 they experiment <XU>
4 	 2 	 (S[dcl]\NP)/S[dcl] 	 2 	 must said
6 	 4 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 do must
6 	 5 	 (S\NP)/(S\NP) 	 2 	 do still
9 	 6 	 (S[b]\NP)/NP 	 2 	 tests do
9 	 7 	 N/N 	 1 	 tests more
9 	 8 	 N/N 	 1 	 tests laboratory
12 	 4 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 experiment must
12 	 11 	 (S\NP)/(S\NP) 	 2 	 experiment then
13 	 12 	 (S[b]\NP)/PP 	 2 	 on experiment
14 	 13 	 PP/NP 	 1 	 animals on
<\s>
<s id="wsj_1246.12"> 17
0 	 1 	 (S[dcl]\NP)/S[dcl] 	 1 	 They said
2 	 3 	 (S[dcl]\NP)/(S[to]\NP) 	 1 	 they hoped
2 	 5 	 ((S[b]\NP)/PP)/NP 	 1 	 they conduct <XB>
3 	 1 	 (S[dcl]\NP)/S[dcl] 	 2 	 hoped said
4 	 3 	 (S[dcl]\NP)/(S[to]\NP) 	 2 	 to hoped
5 	 4 	 (S[to]\NP)/(S[b]\NP) 	 2 	 conduct to
5 	 13 	 ((S\NP)\(S\NP))/NP 	 2 	 conduct by
6 	 5 	 ((S[b]\NP)/PP)/NP 	 3 	 tests conduct
7 	 5 	 ((S[b]\NP)/PP)/NP 	 2 	 on conduct
9 	 7 	 PP/NP 	 1 	 patients on
9 	 8 	 N/N 	 1 	 patients human
9 	 10 	 (NP\NP)/NP 	 1 	 patients in
12 	 10 	 (NP\NP)/NP 	 2 	 U.S. in
12 	 11 	 NP[nb]/N 	 1 	 U.S. the
16 	 13 	 ((S\NP)\(S\NP))/NP 	 3 	 year by
16 	 14 	 N/N 	 1 	 year late
16 	 15 	 N/N 	 1 	 year next
<\s>
<s id="wsj_1246.13"> 17
0 	 1 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 Japan does
0 	 3 	 (S[b]\NP)/NP 	 1 	 Japan have <XB>
1 	 2 	 (S\NP)\(S\NP) 	 2 	 does n't
1 	 16 	 (S[dcl]\S[dcl])\NP 	 1 	 does said
3 	 1 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 have does
6 	 3 	 (S[b]\NP)/NP 	 2 	 patients have
6 	 4 	 N/N 	 1 	 patients enough
6 	 5 	 N/N 	 1 	 patients AIDS
6 	 8 	 (S[b]\NP)/NP 	 1 	 patients do <XB>
8 	 7 	 (S[to]\NP)/(S[b]\NP) 	 2 	 do to
8 	 11 	 ((S\NP)\(S\NP))/NP 	 2 	 do in
10 	 8 	 (S[b]\NP)/NP 	 2 	 experimentation do
10 	 9 	 N/N 	 1 	 experimentation significant
13 	 11 	 ((S\NP)\(S\NP))/NP 	 3 	 country in
13 	 12 	 NP[nb]/N 	 1 	 country that
15 	 16 	 (S[dcl]\S[dcl])\NP 	 2 	 they said
<\s>
<s id="wsj_1246.14"> 17
1 	 0 	 NP[nb]/N 	 1 	 announcement The
1 	 2 	 (S[dcl]\NP)/NP 	 1 	 announcement got
1 	 12 	 (S[dcl]\NP)/NP 	 1 	 announcement moved <XU>
2 	 5 	 ((S\NP)\(S\NP))/NP 	 2 	 got in
4 	 2 	 (S[dcl]\NP)/NP 	 2 	 exposure got
4 	 3 	 N/N 	 1 	 exposure wide
8 	 5 	 ((S\NP)\(S\NP))/NP 	 3 	 media in
8 	 6 	 NP[nb]/N 	 1 	 media the
8 	 7 	 N/N 	 1 	 media Japanese
12 	 11 	 (S\NP)/(S\NP) 	 2 	 moved even
12 	 16 	 (S\NP)\(S\NP) 	 2 	 moved yesterday
15 	 12 	 (S[dcl]\NP)/NP 	 2 	 stocks moved
15 	 13 	 NP[nb]/N 	 1 	 stocks some
15 	 14 	 N/N 	 1 	 stocks pharmaceutical
<\s>
<s id="wsj_1246.15"> 39
2 	 1 	 N/N 	 1 	 Kitamura Takashi
2 	 25 	 (S[dcl]\NP)/S[dcl] 	 1 	 Kitamura said
4 	 5 	 (NP\NP)/NP 	 1 	 director of
4 	 25 	 (S[dcl]\NP)/S[dcl] 	 1 	 director said
8 	 5 	 (NP\NP)/NP 	 2 	 department of
8 	 6 	 NP[nb]/N 	 1 	 department the
8 	 7 	 N/N 	 1 	 department biology
8 	 9 	 (NP\NP)/NP 	 1 	 department at
10 	 11 	 (NP[nb]/N)\NP 	 2 	 Japan 's
13 	 9 	 (NP\NP)/NP 	 2 	 Institute at
13 	 11 	 (NP[nb]/N)\NP 	 1 	 Institute 's
13 	 12 	 N/N 	 1 	 Institute National
13 	 14 	 (NP\NP)/NP 	 1 	 Institute of
15 	 14 	 (NP\NP)/NP 	 2 	 Health of
17 	 18 	 (NP\NP)/NP 	 1 	 secretary of
17 	 25 	 (S[dcl]\NP)/S[dcl] 	 1 	 secretary said
20 	 19 	 NP[nb]/N 	 1 	 government the
20 	 21 	 (NP[nb]/N)\NP 	 2 	 government 's
23 	 18 	 (NP\NP)/NP 	 2 	 center of
23 	 21 	 (NP[nb]/N)\NP 	 1 	 center 's
23 	 22 	 N/N 	 1 	 center AIDS-research
25 	 0 	 S/S 	 1 	 said But
27 	 28 	 (S[dcl]\NP)/(S[adj]\NP) 	 1 	 I 'm
27 	 31 	 (S[adj]\NP)/PP 	 1 	 I optimistic <XB>
28 	 25 	 (S[dcl]\NP)/S[dcl] 	 2 	 'm said
28 	 29 	 (S\NP)\(S\NP) 	 2 	 'm not
31 	 28 	 (S[dcl]\NP)/(S[adj]\NP) 	 2 	 optimistic 'm
31 	 30 	 (S[adj]\NP)/(S[adj]\NP) 	 2 	 optimistic so
32 	 31 	 (S[adj]\NP)/PP 	 2 	 of optimistic
35 	 32 	 PP/NP 	 1 	 use of
35 	 33 	 NP[nb]/N 	 1 	 use its
35 	 34 	 N/N 	 1 	 use future
35 	 36 	 (NP\NP)/NP 	 1 	 use in
38 	 36 	 (NP\NP)/NP 	 2 	 methods in
38 	 37 	 N/N 	 1 	 methods therapeutic
<\s>
<s id="wsj_1246.16"> 23
0 	 1 	 (S[dcl]\NP)/S[dcl] 	 1 	 He said
4 	 2 	 NP[nb]/N 	 1 	 cells some
4 	 3 	 N/N 	 1 	 cells infected
4 	 5 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 cells may
4 	 7 	 (S[b]\NP)/NP 	 1 	 cells have <XB>
4 	 13 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 cells would <XU>
4 	 16 	 S[pss]\NP 	 1 	 cells killed <XU>
5 	 1 	 (S[dcl]\NP)/S[dcl] 	 2 	 may said
5 	 6 	 (S\NP)\(S\NP) 	 2 	 may not
7 	 5 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 have may
10 	 7 	 (S[b]\NP)/NP 	 2 	 antigen have
10 	 8 	 NP[nb]/N 	 1 	 antigen the
10 	 9 	 N/N 	 1 	 antigen relevant
13 	 1 	 (S[dcl]\NP)/S[dcl] 	 2 	 would said
13 	 12 	 (S\NP)/(S\NP) 	 2 	 would so
13 	 14 	 (S\NP)\(S\NP) 	 2 	 would n't
15 	 13 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 be would
16 	 15 	 (S[b]\NP)/(S[pss]\NP) 	 2 	 killed be
16 	 18 	 ((S\NP)\(S\NP))/NP 	 2 	 killed after
18 	 17 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 after even
19 	 18 	 ((S\NP)\(S\NP))/NP 	 3 	 exposure after
19 	 20 	 (NP\NP)/NP 	 1 	 exposure to
22 	 20 	 (NP\NP)/NP 	 2 	 antibody to
22 	 21 	 NP[nb]/N 	 1 	 antibody the
<\s>
<s id="wsj_1246.17"> 22
1 	 0 	 NP[nb]/N 	 1 	 results The
1 	 2 	 (S[dcl]\NP)/(S[to]\NP) 	 1 	 results seem
1 	 6 	 S[adj]\NP 	 1 	 results premature <XB>
2 	 8 	 (S[dcl]\S[dcl])/NP 	 1 	 seem said
3 	 2 	 (S[dcl]\NP)/(S[to]\NP) 	 2 	 to seem
4 	 3 	 (S[to]\NP)/(S[b]\NP) 	 2 	 be to
6 	 4 	 (S[b]\NP)/(S[adj]\NP) 	 2 	 premature be
6 	 5 	 (S[adj]\NP)/(S[adj]\NP) 	 2 	 premature very
10 	 8 	 (S[dcl]\S[dcl])/NP 	 2 	 Miyata said
10 	 9 	 N/N 	 1 	 Miyata Mitsuru
12 	 8 	 (S[dcl]\S[dcl])/NP 	 2 	 editor said
12 	 13 	 (NP\NP)/NP 	 1 	 editor of
15 	 13 	 (NP\NP)/NP 	 2 	 Biotechnology of
15 	 14 	 N/N 	 1 	 Biotechnology Nikkei
21 	 13 	 (NP\NP)/NP 	 2 	 newsletter of
21 	 17 	 NP[nb]/N 	 1 	 newsletter a
21 	 18 	 N/N 	 1 	 newsletter leading
21 	 19 	 N/N 	 1 	 newsletter Japanese
21 	 20 	 N/N 	 1 	 newsletter industry
<\s>
<s id="wsj_1246.18"> 14
1 	 0 	 N/N 	 1 	 Kobayashi Dr.
1 	 2 	 (S[dcl]\NP)/S[em] 	 1 	 Kobayashi responded
3 	 2 	 (S[dcl]\NP)/S[em] 	 2 	 that responded
4 	 5 	 (S[dcl]\NP)/S[dcl] 	 1 	 he thought
5 	 3 	 S[em]/S[dcl] 	 1 	 thought that
7 	 6 	 NP[nb]/N 	 1 	 antibody the
7 	 8 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 antibody could
7 	 10 	 (S[b]\NP)/NP 	 1 	 antibody kill <XB>
8 	 5 	 (S[dcl]\NP)/S[dcl] 	 2 	 could thought
8 	 9 	 (S\NP)\(S\NP) 	 2 	 could potentially
10 	 8 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 kill could
13 	 10 	 (S[b]\NP)/NP 	 2 	 cells kill
13 	 11 	 NP[nb]/N 	 1 	 cells all
13 	 12 	 N/N 	 1 	 cells infected
<\s>
<s id="wsj_1246.19"> 17
1 	 5 	 (S[dcl]\NP)/S[dcl] 	 1 	 he said
4 	 3 	 N/N 	 1 	 Yonehara Dr.
4 	 5 	 (S[dcl]\NP)/S[dcl] 	 1 	 Yonehara said
5 	 0 	 S/S 	 1 	 said But
6 	 7 	 (S[dcl]\NP[thr])/NP 	 1 	 there were
7 	 5 	 (S[dcl]\NP)/S[dcl] 	 2 	 were said
7 	 8 	 (S\NP)\(S\NP) 	 2 	 were still
10 	 7 	 (S[dcl]\NP[thr])/NP 	 2 	 uncertainties were
10 	 9 	 N/N 	 1 	 uncertainties several
10 	 13 	 (NP\NP)/NP 	 1 	 uncertainties regarding
13 	 12 	 (NP\NP)/(NP\NP) 	 2 	 regarding particularly
16 	 13 	 (NP\NP)/NP 	 2 	 effects regarding
16 	 14 	 N/N 	 1 	 effects possible
16 	 15 	 N/N 	 1 	 effects side
<\s>
<s id="wsj_1246.20"> 23
1 	 0 	 NP[nb]/N 	 1 	 antibody Our
1 	 3 	 (S[dcl]\NP)/NP 	 1 	 antibody killed
3 	 2 	 (S\NP)/(S\NP) 	 2 	 killed specifically
3 	 6 	 ((S\NP)\(S\NP))/NP 	 2 	 killed at
3 	 20 	 (S[dcl]\S[dcl])/NP 	 1 	 killed said
5 	 3 	 (S[dcl]\NP)/NP 	 2 	 cells killed
5 	 4 	 N/N 	 1 	 cells infected
9 	 8 	 (N/N)/(N/N) 	 2 	 low very
10 	 6 	 ((S\NP)\(S\NP))/NP 	 3 	 dose at
10 	 7 	 NP[nb]/N 	 1 	 dose a
10 	 9 	 N/N 	 1 	 dose low
13 	 14 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 it can
13 	 16 	 (S[b]\NP)/NP 	 1 	 it kill <XB>
14 	 15 	 (S\NP)\(S\NP) 	 2 	 can also
14 	 20 	 (S[dcl]\S[dcl])/NP 	 1 	 can said
16 	 14 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 kill can
18 	 16 	 (S[b]\NP)/NP 	 2 	 cells kill
18 	 17 	 N/N 	 1 	 cells other
22 	 20 	 (S[dcl]\S[dcl])/NP 	 2 	 Yonehara said
22 	 21 	 N/N 	 1 	 Yonehara Dr.
<\s>
<s id="wsj_1246.21"> 13
0 	 1 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 We do
0 	 3 	 (S[b]\NP)/NP 	 1 	 We know <XB>
1 	 2 	 (S\NP)\(S\NP) 	 2 	 do n't
3 	 1 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 know do
5 	 3 	 (S[b]\NP)/NP 	 2 	 effect know
5 	 4 	 NP[nb]/N 	 1 	 effect the
5 	 6 	 (NP\NP)/NP 	 1 	 effect of
5 	 9 	 (NP\NP)/NP 	 1 	 effect on
8 	 6 	 (NP\NP)/NP 	 2 	 antibody of
8 	 7 	 NP[nb]/N 	 1 	 antibody our
12 	 9 	 (NP\NP)/NP 	 2 	 body on
12 	 10 	 NP[nb]/N 	 1 	 body the
12 	 11 	 N/N 	 1 	 body human
<\s>
<s id="wsj_1246.22"> 42
0 	 1 	 (S[dcl]\NP)/(S[pss]\NP) 	 1 	 AIDS is
0 	 3 	 (S[pss]\NP)/NP 	 1 	 AIDS considered <XB>
1 	 2 	 (S\NP)\(S\NP) 	 2 	 is n't
1 	 9 	 (S\S)/S[dcl] 	 1 	 is --
3 	 1 	 (S[dcl]\NP)/(S[pss]\NP) 	 2 	 considered is
6 	 3 	 (S[pss]\NP)/NP 	 2 	 problem considered
6 	 4 	 NP[nb]/N 	 1 	 problem a
6 	 5 	 N/N 	 1 	 problem widespread
6 	 7 	 (NP\NP)/NP 	 1 	 problem in
8 	 7 	 (NP\NP)/NP 	 2 	 Japan in
11 	 10 	 NP[nb]/N 	 1 	 government the
11 	 12 	 (S[dcl]\NP)/NP 	 1 	 government reports
12 	 9 	 (S\S)/S[dcl] 	 2 	 reports --
14 	 13 	 (N/N)/(N/N) 	 2 	 1,000 about
16 	 12 	 (S[dcl]\NP)/NP 	 2 	 carriers reports
16 	 14 	 N/N 	 1 	 carriers 1,000
16 	 15 	 N/N 	 1 	 carriers known
16 	 17 	 (NP\NP)/NP 	 1 	 carriers of
19 	 17 	 (NP\NP)/NP 	 2 	 virus of
19 	 18 	 NP[nb]/N 	 1 	 virus the
23 	 22 	 N/N 	 1 	 companies many
23 	 24 	 (S[dcl]\NP)/(S[pt]\NP) 	 1 	 companies have
23 	 25 	 ((S[pt]\NP)/PP)/NP 	 1 	 companies poured <XB>
23 	 34 	 (S[ng]\NP)/(S[to]\NP) 	 1 	 companies hoping <XB>
23 	 36 	 (S[b]\NP)/PP 	 1 	 companies cash <XB>
25 	 24 	 (S[dcl]\NP)/(S[pt]\NP) 	 2 	 poured have
25 	 30 	 ((S\NP)\(S\NP))/NP 	 2 	 poured in
27 	 25 	 ((S[pt]\NP)/PP)/NP 	 3 	 resources poured
27 	 26 	 N/N 	 1 	 resources substantial
28 	 25 	 ((S[pt]\NP)/PP)/NP 	 2 	 into poured
29 	 28 	 PP/NP 	 1 	 research into
32 	 30 	 ((S\NP)\(S\NP))/NP 	 3 	 years in
32 	 31 	 N/N 	 1 	 years recent
35 	 34 	 (S[ng]\NP)/(S[to]\NP) 	 2 	 to hoping
36 	 35 	 (S[to]\NP)/(S[b]\NP) 	 2 	 cash to
36 	 37 	 (S\NP)\(S\NP) 	 2 	 cash in
38 	 36 	 (S[b]\NP)/PP 	 2 	 on cash
41 	 38 	 PP/NP 	 1 	 cure on
41 	 39 	 NP[nb]/N 	 1 	 cure a
41 	 40 	 N/N 	 1 	 cure possible
<\s>
<s id="wsj_1246.23"> 33
1 	 0 	 N/N 	 1 	 Kitamura Dr.
1 	 2 	 (S[dcl]\NP)/S[dcl] 	 1 	 Kitamura said
4 	 3 	 (N/N)/(N/N) 	 2 	 35 about
5 	 4 	 N/N 	 1 	 projects 35
5 	 6 	 (S[dcl]\NP)/PP 	 1 	 projects are
6 	 2 	 (S[dcl]\NP)/S[dcl] 	 2 	 are said
6 	 7 	 (S\NP)\(S\NP) 	 2 	 are currently
6 	 10 	 ((S\NP)\(S\NP))/NP 	 2 	 are in
8 	 6 	 (S[dcl]\NP)/PP 	 2 	 under are
9 	 8 	 PP/NP 	 1 	 way under
11 	 10 	 ((S\NP)\(S\NP))/NP 	 3 	 Japan in
14 	 2 	 (S[dcl]\NP)/S[dcl] 	 2 	 that said
16 	 15 	 N/N 	 1 	 researchers Japanese
16 	 17 	 (NP\NP)/NP 	 1 	 researchers in
16 	 21 	 (S[dcl]\NP)/(S[pt]\NP) 	 1 	 researchers have
16 	 22 	 (S[pt]\NP)/S[adj] 	 1 	 researchers made <XB>
20 	 17 	 (NP\NP)/NP 	 2 	 year in
20 	 18 	 NP[nb]/N 	 1 	 year the
20 	 19 	 N/N 	 1 	 year past
21 	 14 	 S[em]/S[dcl] 	 1 	 have that
22 	 21 	 (S[dcl]\NP)/(S[pt]\NP) 	 2 	 made have
23 	 22 	 (S[pt]\NP)/S[adj] 	 2 	 available made
23 	 27 	 (S[adj]\S[adj])/NP 	 1 	 available to
23 	 30 	 (S[adj]\S[adj])/NP 	 1 	 available for
26 	 23 	 S[adj]/NP 	 1 	 cures available
26 	 24 	 N/N 	 1 	 cures three
26 	 25 	 N/N 	 1 	 cures possible
29 	 27 	 (S[adj]\S[adj])/NP 	 2 	 researchers to
29 	 28 	 N/N 	 1 	 researchers American
32 	 30 	 (S[adj]\S[adj])/NP 	 2 	 tests for
32 	 31 	 N/N 	 1 	 tests clinical
<\s>
<s id="wsj_1246.24"> 29
0 	 1 	 (S[dcl]\NP)/S[em] 	 1 	 He said
2 	 1 	 (S[dcl]\NP)/S[em] 	 2 	 that said
4 	 5 	 (NP\NP)/NP 	 1 	 scientists from
4 	 9 	 S[dcl]\NP 	 1 	 scientists meet
8 	 5 	 (NP\NP)/NP 	 2 	 countries from
8 	 6 	 NP[nb]/N 	 1 	 countries the
8 	 7 	 N/N 	 1 	 countries two
9 	 3 	 (S/S)/S[dcl] 	 2 	 meet when
9 	 10 	 (S\NP)\(S\NP) 	 2 	 meet again
9 	 11 	 ((S\NP)\(S\NP))/NP 	 2 	 meet in
9 	 13 	 ((S\NP)\(S\NP))/NP 	 2 	 meet in
12 	 11 	 ((S\NP)\(S\NP))/NP 	 3 	 January in
15 	 13 	 ((S\NP)\(S\NP))/NP 	 3 	 Orleans in
15 	 14 	 N/N 	 1 	 Orleans New
18 	 17 	 NP[nb]/N 	 1 	 Japanese the
18 	 19 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 Japanese will
18 	 20 	 ((S[b]\NP)/PP)/NP 	 1 	 Japanese present <XB>
19 	 2 	 S[em]/S[dcl] 	 1 	 will that
19 	 3 	 (S/S)/S[dcl] 	 1 	 will when
20 	 19 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 present will
22 	 21 	 (((N/N)/(N/N))/((N/N)/(N/N)))/(S[asup]\NP) 	 4 	 least at
23 	 21 	 (((N/N)/(N/N))/((N/N)/(N/N)))/(S[asup]\NP) 	 3 	 three at
24 	 23 	 (N/N)/(N/N) 	 2 	 more three
25 	 20 	 ((S[b]\NP)/PP)/NP 	 3 	 drugs present
25 	 24 	 N/N 	 1 	 drugs more
26 	 20 	 ((S[b]\NP)/PP)/NP 	 2 	 for present
28 	 26 	 PP/NP 	 1 	 testing for
28 	 27 	 N/N 	 1 	 testing human
<\s>
<s id="wsj_1246.25"> 13
0 	 1 	 (S[dcl]\NP)/NP 	 1 	 AZT is
3 	 2 	 NP[nb]/N 	 1 	 world the
3 	 4 	 (NP[nb]/N)\NP 	 2 	 world 's
7 	 1 	 (S[dcl]\NP)/NP 	 2 	 medicine is
7 	 4 	 (NP[nb]/N)\NP 	 1 	 medicine 's
7 	 5 	 N/N 	 1 	 medicine only
7 	 6 	 N/N 	 1 	 medicine prescription
7 	 8 	 (S[pss]\NP)/PP 	 1 	 medicine approved <XB>
9 	 8 	 (S[pss]\NP)/PP 	 2 	 for approved
10 	 9 	 PP/(S[ng]\NP) 	 1 	 treating for
12 	 10 	 (S[ng]\NP)/NP 	 2 	 disease treating
12 	 11 	 NP[nb]/N 	 1 	 disease the
<\s>
<s id="wsj_1246.26"> 16
1 	 0 	 N/N 	 1 	 PLC Wellcome
1 	 9 	 (S[dcl]\NP)/NP 	 1 	 PLC sells
7 	 3 	 NP[nb]/N 	 1 	 maker a
7 	 4 	 N/N 	 1 	 maker major
7 	 5 	 N/N 	 1 	 maker British
7 	 6 	 N/N 	 1 	 maker pharmaceutical
7 	 9 	 (S[dcl]\NP)/NP 	 1 	 maker sells
9 	 12 	 ((S\NP)\(S\NP))/NP 	 2 	 sells under
11 	 9 	 (S[dcl]\NP)/NP 	 2 	 drug sells
11 	 10 	 NP[nb]/N 	 1 	 drug the
15 	 12 	 ((S\NP)\(S\NP))/NP 	 3 	 Retrovir under
15 	 13 	 NP[nb]/N 	 1 	 Retrovir the
15 	 14 	 N/N 	 1 	 Retrovir name
<\s>
<s id="wsj_1246.27"> 14
2 	 0 	 NP[nb]/N 	 1 	 spokesman A
2 	 1 	 N/N 	 1 	 spokesman Wellcome
2 	 3 	 (S[dcl]\NP)/(S[to]\NP) 	 1 	 spokesman declined
2 	 5 	 (S[b]\NP)/PP 	 1 	 spokesman comment <XB>
4 	 3 	 (S[dcl]\NP)/(S[to]\NP) 	 2 	 to declined
5 	 4 	 (S[to]\NP)/(S[b]\NP) 	 2 	 comment to
6 	 5 	 (S[b]\NP)/PP 	 2 	 on comment
8 	 6 	 PP/NP 	 1 	 discovery on
8 	 7 	 NP[nb]/N 	 1 	 discovery the
8 	 9 	 (NP\NP)/NP 	 1 	 discovery of
8 	 12 	 (NP\NP)/NP 	 1 	 discovery in
11 	 9 	 (NP\NP)/NP 	 2 	 antibody of
11 	 10 	 NP[nb]/N 	 1 	 antibody the
13 	 12 	 (NP\NP)/NP 	 2 	 Japan in
<\s>
<s id="wsj_1246.28"> 35
2 	 1 	 N/N 	 1 	 Porter Andrew
2 	 14 	 (S[dcl]\NP)/S[dcl] 	 1 	 Porter said
6 	 4 	 NP[nb]/N 	 1 	 analyst a
6 	 5 	 N/N 	 1 	 analyst drug-industry
6 	 7 	 (NP\NP)/NP 	 1 	 analyst at
6 	 14 	 (S[dcl]\NP)/S[dcl] 	 1 	 analyst said
10 	 7 	 (NP\NP)/NP 	 2 	 Co. at
10 	 8 	 N/N 	 1 	 Co. Nikko
10 	 9 	 N/N 	 1 	 Co. Securities
10 	 11 	 (NP\NP)/NP 	 1 	 Co. in
12 	 11 	 (NP\NP)/NP 	 2 	 London in
14 	 0 	 S/S 	 1 	 said But
17 	 16 	 NP[nb]/N 	 1 	 product the
17 	 18 	 (S[dcl]\NP)/(S[to]\NP) 	 1 	 product were
17 	 22 	 S[pss]\NP 	 1 	 product developed <XB>
18 	 15 	 (S/S)/S[dcl] 	 2 	 were if
19 	 18 	 (S[dcl]\NP)/(S[to]\NP) 	 2 	 to were
20 	 19 	 (S[to]\NP)/(S[b]\NP) 	 2 	 be to
22 	 20 	 (S[b]\NP)/(S[pss]\NP) 	 2 	 developed be
22 	 21 	 (S\NP)/(S\NP) 	 2 	 developed successfully
23 	 24 	 (S[dcl]\NP)/(S[b]\NP) 	 1 	 it would
23 	 25 	 (S[b]\NP)/NP 	 1 	 it represent <XB>
24 	 14 	 (S[dcl]\NP)/S[dcl] 	 2 	 would said
24 	 15 	 (S/S)/S[dcl] 	 1 	 would if
25 	 24 	 (S[dcl]\NP)/(S[b]\NP) 	 2 	 represent would
28 	 25 	 (S[b]\NP)/NP 	 2 	 threat represent
28 	 26 	 NP[nb]/N 	 1 	 threat a
28 	 27 	 N/N 	 1 	 threat potential
28 	 29 	 (NP\NP)/NP 	 1 	 threat to
32 	 29 	 (NP\NP)/NP 	 2 	 viability to
32 	 30 	 NP[nb]/N 	 1 	 viability the
32 	 31 	 N/N 	 1 	 viability long-term
32 	 33 	 (NP\NP)/NP 	 1 	 viability of
34 	 33 	 (NP\NP)/NP 	 2 	 Retrovir of
<\s>
